About 31 results found for searched term "ET receptor antagonist 1" (0.077 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M43590 | ET receptor antagonist 1 | Estrogen Receptor |
| ET receptor antagonist 1 is an orally active ET receptor antagonist (IC50=0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). | ||
| M1866 | VU 0255035 | AChR/AChE |
| VU 0255035 is a highly selective M1 muscarinic acetylcholine receptor (mAChR) antagonist (Ki = 14.87 nM). | ||
| M1917 | Mozavaptan | Vasopressin Receptor |
| OPC-31260 | ||
| Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. | ||
| M2134 | Vortioxetine hydrobromide | 5-HT Receptor |
| Lu AA21004 | ||
| Vortioxetine hydrobromide (Lu AA21004) is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist and a 5-HT transporter (5-HTT) inhibitor in vitro. | ||
| M3072 | Timolol Maleate | Adrenergic Receptor |
| (S)-Timolol Maleate; L-714465 Maleate; MK 950 | ||
| Timolol Maleate is a non-selective, beta-adrenergic receptor antagonist for β1/β2 with Ki of 1.97 nM/2.0 nM. | ||
| M3234 | (R)-Bicalutamide | Androgen Receptor |
| (R)-Bicalutamide is an active competitive non-steroidal androgen receptor antagonist with an IC50 of 0.17 μM for MDA 453 cells. | ||
| M3261 | Almorexant | OX Receptor |
| ACT-078573 | ||
| Almorexant is a competitive OX1 and OX2 orexin receptor antagonist with IC50 of 13 and 8 nM, respectively. | ||
| M3331 | Trospium chloride | AChR/AChE |
| Trospium chloride is an orally active, competitive muscarinic cholinergic receptors (mAChRs) antagonist. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors. | ||
| M3480 | Tolvaptan | Vasopressin Receptor |
| OPC-41061 | ||
| Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation. | ||
| M3570 | Candesartan Cilexetil | ATM/ATR |
| TCV-116 | ||
| Candesartan Cilexetil is a specific nonpeptide Ang II receptor (ATR) antagonist and the procompound of candesartan which is an ATR antagonist with an IC50 of 15 μg/kg. | ||
| M3947 | ELN 441958 | Bradykinin Receptor |
| ELN-441958 is a potent, neutral, competitive and selective oral bioavailable bradykinin B1 receptor antagonist with a Ki of 0.26 nM against native human bradykinin B1 receptor. | ||
| M4833 | Eliprodil | GluR |
| SL-820715 | ||
| Eliprodil is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM). | ||
| M5135 | Ro-46-2005 | Endothelin Receptor |
| Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM. | ||
| M5544 | Cyproterone Acetate | Androgen Receptor |
| Cyproterone acetate is an androgen receptor (AR) antagonist with IC50 of 7.1 nM. | ||
| M5835 | Ondansetron Hydrochloride Dihydrate | 5-HT Receptor |
| GR 38032; SN 307; NSC 665799 | ||
| Ondansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist (Ki=6.16 nM), with low affinity for dopamine receptors. | ||
| M6374 | A-804598 | P2 Receptor |
| A804598 | ||
| A-804598 is a CNS penetrant, competitive and selective P2X7 receptor antagonist with IC50s of 9 nM, 10 nM and 11 nM for mouse, rat and human P2X7 receptors, respectively. | ||
| M6457 | AR-C 118925XX | P2 Receptor |
| ARC118925XX | ||
| AR-C 118925XX is a selective, competitive P2Y2 receptor antagonist. AR-C 118925XX is inactive against a panel of 37 other receptors at a concentration of 10 μM. AR-C 118925XX inhibits ATP-γS-induced mucin secretion in bronchial epithelial cells (IC50 = 1 μM). AR-C 118925XX inhibits P2Y2 receptor-induced β-arrestin translocation in vitro (pA2 = 37.2-51.3 nM). | ||
| M6619 | CNQX | GluR |
| FG9065 | ||
| CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist. | ||
| M6621 | Conantokin-R | Others |
| Con-R | ||
| Conantokin-R is a potent, non-competitive NMDA receptor peptide antagonist with an IC50 of 93 nM.Conantokin-R is also NR2 subunit selective. It inhibits the inward current induced by NMDA in CNS neurons (IC50 = 350 nM). In addition, Conantokin R bound to Zn2+ and Mg2+ with Kd of 0.15 μM and 6.5 μM, respectively. | ||
| M6710 | Endoxifen Z-isomer hydrochloride | Estrogen Receptor |
| Endoxifen Z-isomer HCl | ||
| Endoxifen Z-isomer hydrochloride is a Tamoxifen metabolite and a potent estrogen receptor (ER) antagonist that concentration-dependently inhibits hERG with an IC50 value of 1.6 μM. | ||
| M7327 | Lintitript | Cholecystokinin Receptor |
| SR 27897 | ||
| Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). | ||
| M25611 | Cyclosomatostatin acetate | Somatostatin Receptor |
| cycloSST | ||
| Cyclosomatostatin acetate is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin acetate can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells. | ||
| M7886 | LY255283 | Leukotriene Receptor |
| LY255283 is a competitive leukotriene B4 receptor antagonist, with an IC50 of about 100 nM. | ||
| M8700 | PCS1055 dihydrochloride | Others |
| PCS1055 is a potent and selective muscarinic M4 acetylcholine receptor competitive antagonist that exhibits >100-fold selectivity over M1-, M3-, and M5-receptors and 30-fold selectivity at the M2 receptor. | ||
| M8764 | MM11253 | RAR/RXR |
| SR11253 | ||
| MM11253 (SR11253) is a high-affinity RARγ-selective retinoid acid (RA) receptor antagonist (IC50 = 44 nM against ATRA for binding RARγ; IC50 =1 μM in case of RARα, RARβ, RXRα). | ||
| M8766 | Atrasentan hydrochloride | Endothelin Receptor |
| ABT-627 hydrochloride; Abbott 147627 | ||
| Atrasentan hydrochloride (ABT-627 hydrochloride) is a potent, orally active, selective endothelin A (ETA) receptor antagonist that inhibits ETA activity and blocks endothelin-induced cellular proliferation with an IC50 value of 0.0551 nM. It can be used in studies related to prostate cancer as well as IgA nephropathy (IgAN). It can be used in prostate cancer and IgA nephropathy (IgAN) related studies. | ||
| M9839 | Lemborexant | OX Receptor |
| E-2006 | ||
| Lemborexant (E-2006) is an orally active, competitive and reversible dual OX1 and OX2 receptors antagonist, with IC50 values of 6.1 nM and 2.6 nM, respectively. | ||
| M11344 | JMV 2959 | Ghrelin Receptor/GHSR |
| JMV 2959 is a growth hormone secretin receptor type 1A (GHS-R1A) antagonist that acts on LC-PK1 cells and inhibits GHS-R1A with an IC50 value of 32±3 nM. | ||
| M13375 | Cetrorelix Acetate | LHRH/GnRH |
| Cetrorelix Acetate (SB-75 acetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM. Sequence：Ac-D2Nal-D4Cpa-D3Pal-Ser-Tyr-DCit-Leu-Arg-Pro-DAla-NH2 | ||
| M13865 | Alprenolol | 5-HT Receptor |
| (RS)-Alprenolol; dl-Alprenolol | ||
| Alprenolol is a non-selective beta blocker as well as 5-HT1A receptor antagonist. The reference for administration is 10 mg/kg. | ||
| M13866 | Alprenolol hydrochloride | 5-HT Receptor |
| (RS)-Alprenolol hydrochloride; dl-Alprenolol hydrochloride | ||
| Alprenolol (hydrochloride) is a non-selective beta blocker as well as 5-HT1A receptor antagonist. The reference for administration is 10 mg/kg. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
